Schroder Investment Management Group Acquires Shares of 117,356 Luminex Co. (LMNX)
Schroder Investment Management Group acquired a new position in Luminex Co. (NASDAQ:LMNX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 117,356 shares of the medical instruments supplier’s stock, valued at approximately $3,557,000. Schroder Investment Management Group owned 0.26% of Luminex as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also modified their holdings of LMNX. Bessemer Group Inc. grew its position in Luminex by 949.0% in the third quarter. Bessemer Group Inc. now owns 531,851 shares of the medical instruments supplier’s stock worth $16,121,000 after acquiring an additional 481,151 shares during the period. BlackRock Inc. grew its position in Luminex by 6.4% in the second quarter. BlackRock Inc. now owns 6,593,040 shares of the medical instruments supplier’s stock worth $194,692,000 after acquiring an additional 395,549 shares during the period. WINTON GROUP Ltd purchased a new position in Luminex in the second quarter worth approximately $11,507,000. PNC Financial Services Group Inc. grew its position in Luminex by 26,778.2% in the third quarter. PNC Financial Services Group Inc. now owns 221,476 shares of the medical instruments supplier’s stock worth $6,712,000 after acquiring an additional 220,652 shares during the period. Finally, Russell Investments Group Ltd. grew its position in Luminex by 81.4% in the third quarter. Russell Investments Group Ltd. now owns 262,184 shares of the medical instruments supplier’s stock worth $7,882,000 after acquiring an additional 117,685 shares during the period. Institutional investors own 83.82% of the company’s stock.
Several research analysts recently weighed in on LMNX shares. BidaskClub lowered Luminex from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 22nd. Zacks Investment Research upgraded Luminex from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. ValuEngine upgraded Luminex from a “buy” rating to a “strong-buy” rating in a research report on Monday, October 29th. Finally, Citigroup lowered their price objective on Luminex from $34.00 to $33.00 and set a “neutral” rating for the company in a research report on Tuesday, November 6th. Five investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $28.40.
Luminex (NASDAQ:LMNX) last released its quarterly earnings results on Monday, November 5th. The medical instruments supplier reported $0.05 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.03). Luminex had a return on equity of 5.99% and a net margin of 5.65%. The firm had revenue of $72.40 million for the quarter, compared to analysts’ expectations of $74.05 million. During the same quarter in the prior year, the business earned $0.13 earnings per share. The company’s quarterly revenue was down 2.3% on a year-over-year basis. As a group, equities research analysts predict that Luminex Co. will post 0.58 EPS for the current year.
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.
Featured Article: What are the Different Types of Leveraged Buyouts?
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.